Food allergy is one of the most prevalent chronic non-infectious diseases globally, with an increasing incidence.In 2024, the European Academy of Allergy and Clinical Immunology published guidelines on the management of immunoglobulin E-mediated food allergy.The guidelines employ the Grading of Recommendations Assessment, Development, and Evaluation evaluation system and put forth 14 recommendations pertaining to 5 key areas: dietary intervention, psychological support, management plans, allergen-specific immunotherapy, and biological agents.This article interprets the guidelines from the perspective of strength, reasons, and practical significance.The aim is to provide a reference for clinical work and to improve the level of management of food allergies.

The incidence of food allergy is on the rise, with the capacity to impact various organ systems, including but not limited to the skin, respiratory system, gastrointestinal system, cardiovascular system, and nervous system.In extreme cases, these allergies can result in anaphylaxis.Immunoglobulin E (IgE)-mediated type Ⅰ hypersensitivity reactions are a common cause of food allergy and are the primary pathway to anaphylaxis.Omalizumab, the first biologic therapy approved for the treatment of IgE-mediated food allergy, can be incorporated into a comprehensive management strategy for food allergy sufferers.However, due to the lack of definitive evidence, the safety and efficacy of Omalizumab in all patients with IgE-mediated food allergy remain equivocal.In light of this, Global Allergy and Asthma European Network Anaphylaxis Centres of Reference and Excellence convened a panel of experts to deliberate on the appropriate patient and therapeutic strategies for Omalizumab, culminating in a consensus statement.This paper aimed to interpret the consensus proposed by the experts, with the objective of assisting clinicians in better understanding the application of Omazumab in patients with IgE-mediated food allergy.

The Global Initiative for Asthma (GINA) 2025 has conducted a comprehensive revision of the diagnosis and management of asthma in children aged 5 years and younger.The most important update is the first-time proposal of the specific conditions for asthma diagnosis in this age group.This article aims to interpret the relevant content of diagnosis, exacerbation management, assessment and treatment of asthma in children aged 5 years and younger in GINA 2025.It is hoped that this will provide a reference for clinical practice and enhance the management of asthma in children aged 5 years and younger.

The Global Initiative for Asthma (GINA) continues to optimize asthma treatment strategies and has introduced the concepts of anti-inflammatory reliever (AIR) and maintenance and reliever therapy(MART). AIR mainly includes Budesonide-Formoterol, Beclomethasone-Formoterol, and inhaled corticosteroids(ICS)combined with short-acting beta2-agonist.MART refers to a treatment regimen that utilizes the same ICS-Formoterol combination for both maintenance and reliever therapy.Currently, AIR and MART are recommended for the treatment of asthma in children aged 6 years and older, adolescents and adults.This article provides an interpretation of the pediatric AIR and MART content in GINA 2025, highlighting their clinical application in pediatric asthma treatment and their role in asthma action plans, with the aim of providing a reference for clinicians to optimize the treatment of pediatric asthma.

Food allergy is one of the most prevalent chronic non-infectious diseases globally, with an increasing incidence.In 2024, the European Academy of Allergy and Clinical Immunology published guidelines on the management of immunoglobulin E-mediated food allergy.The guidelines employ the Grading of Recommendations Assessment, Development, and Evaluation evaluation system and put forth 14 recommendations pertaining to 5 key areas: dietary intervention, psychological support, management plans, allergen-specific immunotherapy, and biological agents.This article interprets the guidelines from the perspective of strength, reasons, and practical significance.The aim is to provide a reference for clinical work and to improve the level of management of food allergies.

The incidence of food allergy is on the rise, with the capacity to impact various organ systems, including but not limited to the skin, respiratory system, gastrointestinal system, cardiovascular system, and nervous system.In extreme cases, these allergies can result in anaphylaxis.Immunoglobulin E (IgE)-mediated type Ⅰ hypersensitivity reactions are a common cause of food allergy and are the primary pathway to anaphylaxis.Omalizumab, the first biologic therapy approved for the treatment of IgE-mediated food allergy, can be incorporated into a comprehensive management strategy for food allergy sufferers.However, due to the lack of definitive evidence, the safety and efficacy of Omalizumab in all patients with IgE-mediated food allergy remain equivocal.In light of this, Global Allergy and Asthma European Network Anaphylaxis Centres of Reference and Excellence convened a panel of experts to deliberate on the appropriate patient and therapeutic strategies for Omalizumab, culminating in a consensus statement.This paper aimed to interpret the consensus proposed by the experts, with the objective of assisting clinicians in better understanding the application of Omazumab in patients with IgE-mediated food allergy.

The Global Initiative for Asthma (GINA) 2025 has conducted a comprehensive revision of the diagnosis and management of asthma in children aged 5 years and younger.The most important update is the first-time proposal of the specific conditions for asthma diagnosis in this age group.This article aims to interpret the relevant content of diagnosis, exacerbation management, assessment and treatment of asthma in children aged 5 years and younger in GINA 2025.It is hoped that this will provide a reference for clinical practice and enhance the management of asthma in children aged 5 years and younger.

The Global Initiative for Asthma (GINA) continues to optimize asthma treatment strategies and has introduced the concepts of anti-inflammatory reliever (AIR) and maintenance and reliever therapy(MART). AIR mainly includes Budesonide-Formoterol, Beclomethasone-Formoterol, and inhaled corticosteroids(ICS)combined with short-acting beta2-agonist.MART refers to a treatment regimen that utilizes the same ICS-Formoterol combination for both maintenance and reliever therapy.Currently, AIR and MART are recommended for the treatment of asthma in children aged 6 years and older, adolescents and adults.This article provides an interpretation of the pediatric AIR and MART content in GINA 2025, highlighting their clinical application in pediatric asthma treatment and their role in asthma action plans, with the aim of providing a reference for clinicians to optimize the treatment of pediatric asthma.

Fungus is one of common allergens in allergic disease that affects the susceptibility, severity, and disease control of allergic airway disease in children.A spectrum of respiratory diseases associated with fungal sensitization has been described as allergic fungal airway disease (AFAD), including severe asthma with fungal sensitization, allergic bronchopulmonary aspergillosis, thunderstorm asthma, and allergic fungal rhinosinusitis.Glucocorticoids, biologics, antifungal therapy, and immunotherapy can reduce the airway inflammation, fungal burden, and tissue damage associated with AFAD.This review introduced fungus, the mechanism of fungal sensitization and the detection, as well as the scope and treatment of AFAD in children, aiming to improve the understanding of AFAD among pediatricians.

Trained immunity has been a novel term in immunology for over a decade, referring to the memory immunity produced by the innate immune system upon re-stimulation.Non-specific training of the immune system enhances the immune defense function and is also involved in allergic inflammation and autoimmune diseases.An increasing number of researchers are focusing on the role of immune training in the prevention, treatment, onset and progression of diseases.This review explains the definition, mechanism, and inducers of immune training and its impact on children′s health and disease, in order to enhance pediatricians′ comprehension of trained immunity.